FDA Approves sNDA for Taletrectinib in ROS1+ NSCLC

The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for taletrectinib (Ibtrozi), updating the product label to incorporate extended duration of response (DOR) data for patients with tyrosine kinase inhibitor (TKI)-naïve, locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The approval was granted four months ahead of the Prescription Drug User Fee Act (PDUFA) target date.

Taletrectinib is an oral, potent, central nervous system (CNS)-active, selective, next-generation ROS1 inhibitor. The FDA initially granted full approval to taletrectinib in June 2025 across lines of therapy for adult patients with locally advanced or metastatic ROS1+ NSCLC. The updated label reflects a median DOR of 49.7 months in TKI-naïve patients from the pivotal TRUST-I (NCT04395677) study, demonstrating over 4 years of sustained clinical benefit.

Long-Term Efficacy and the TRUST Clinical Program

The sNDA approval incorporates an additional 14 months of data from an August 2025 data cutoff across the TRUST-I and TRUST-II (NCT04919811) studies. The updated label reflects a median follow-up of 51 months for participants in TRUST-I. These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 and published in the Journal of Clinical Oncology.

The broader TRUST clinical trial framework includes four key studies:

• TRUST-I: A phase 2 single-arm trial evaluating taletrectinib in 173 adult patients with advanced ROS1+ NSCLC in China.
• TRUST-II (NCT04919811): A global phase 2 single-arm trial enrolling 189 adult patients with advanced ROS1+ NSCLC.
• TRUST-III (NCT06564324): A confirmatory randomized phase 3 trial comparing taletrectinib with crizotinib in 194 TKI-naïve patients with advanced ROS1+ NSCLC in China.
• TRUST-IV (NCT07154706): A phase 3 placebo-controlled trial evaluating adjuvant taletrectinib in approximately 180 patients with resected early-stage ROS1+ NSCLC, using disease-free survival as the primary endpoint.

ROS1 alterations occur in approximately 2% of NSCLC cases, a disease category accounting for over 1 million global diagnoses annually. Central nervous system disease represents a primary concern, as 35% of patients with newly diagnosed metastatic ROS1+ NSCLC present with brain metastases, and 50% of pretreated patients develop CNS disease progression.

Key Clinical Takeaways for Oncology Nurses

Efficacy and Trial Scope

• Sustained Response Benchmark: Updated label data establish a median DOR of 49.7 months in TKI-naïve patients, providing long-term efficacy metrics for patient counseling.
• CNS Surveillance Necessity: With 35% of newly diagnosed patients presenting with brain metastases and 50% of pretreated patients developing CNS progression, ongoing neurological monitoring is critical.
• Clinical Trial Awareness: Oncology nurses should note ongoing clinical trials, including the phase 3 TRUST-IV adjuvant trial for patients with resected early-stage ROS1+ NSCLC.

Safety Profile, Adverse Event Monitoring, and Drug Interactions

• Longer-term follow-up revealed no new safety signals, leaving the safety sections of the product label unchanged.
• Hepatotoxicity is a primary warning. Increased AST and ALT occurred in 88% and 85% of patients, respectively, with Grade 3/4 elevations reported in 10% (AST) and 13% (ALT). Fatal liver events occurred in 0.6% of patients, with a median onset of 15 days. Interstitial lung disease (ILD)/pneumonitis occurred in 2.3% of patients (1.1% Grade 3/4), with a median onset of 3.8 months.
• Concentration-dependent QTc interval prolongation occurred in clinical studies. A QTcF increase exceeding 60 msec from baseline occurred in 13% of patients, and QTcF exceeding 500 msec occurred in 2.6%. Median time to onset of QTc prolongation was 22 days. To manage QTc risks, taletrectinib must be taken on an empty stomach.
• Hyperuricemia was reported in 14% of patients, with 16% of those requiring urate-lowering therapy. Myalgia occurred in 10% of patients, with median onset at 11 days. Skeletal fractures occurred in 3.4% of patients (1.4% Grade 3), with a median onset of 10.7 months.
• Adverse reactions occurring in ≥20% of patients include diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%). Grade 3/4 laboratory abnormalities occurring in ≥5% of patients include increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased CPK (5%).
• Concomitant use of strong or moderate CYP3A inhibitors/inducers and QTc-prolonging drugs must be avoided. Proton pump inhibitors (PPIs) and H2 receptor antagonists should be avoided. If an acid-reducing agent is required, locally acting antacids must be administered at least 2 hours before or 2 hours after taletrectinib. Advise lactating women not to breastfeed during treatment and for 3 weeks after the final dose. Due to photosensitivity risks, patients should minimize sun exposure and use broad-spectrum sunscreen during treatment and for at least 5 days following discontinuation.

Key Clinical Takeaways for Oncology Nurses

Patient Safety and Management

• Early Hepatic Lab Monitoring: Schedule baseline and routine liver function tests, focusing closely on the first month of treatment due to a 15-day median onset for AST/ALT elevations.
• Strict Administration Guidance: Instruct patients to take taletrectinib on an empty stomach to avoid food-induced increases in QTc interval prolongation.
• Acid Reducer Coadministration: Avoid PPIs and H2 blockers; ensure locally acting antacids are taken at least 2 hours before or 2 hours after taletrectinib doses.
• Respiratory Assessment: Monitor for signs of ILD/pneumonitis, noting a median onset of 3.8 months.
• Photosensitivity Education: Counsel patients to apply broad-spectrum sunscreen and wear protective clothing during treatment and for 5 days post-discontinuation.
• Lactation Restrictions: Instruct female patients to refrain from breastfeeding during treatment and for 3 weeks following the last dose.

Reference

1. Nuvation Bio Inc. Nuvation Bio announces FDA approval of supplemental New Drug Application for IBTROZI® (taletrectinib) with updated duration of response in TKI-naïve advanced ROS1-positive non-small cell lung cancer. PR Newswire. Published September 17, 2026. Accessed September 17, 2026. https://www.prnewswire.com/news-releases/nuvation-bio-announces-fda-approval-of-supplemental-new-drug-application-for-ibtrozi-taletrectinib-with-updated-duration-of-response-in-tki-naive-advanced-ros1-positive-non-small-cell-lung-cancer-302881232.html